|
|
||||||||
1 From the Singapore National Eye Centre, Singapore Eye Research Institute; and the 2 Department of Clinical Research, Singapore General Hospital.
| Abstract |
|---|
|
|
|---|
METHODS. Matched pterygium and superior conjunctiva tissue were obtained in 36 eyes of 36 patients undergoing pterygium excision with conjunctival autografting (24 primary pterygia, 12 recurrent pterygia). Epithelial and fibrovascular layers were separated for analysis. Matched superior conjunctiva obtained at the time of surgery were used as controls. Samples were prepared according to Thompsons method, and flow cytometry was performed with a BectonDickinson FACScan. Analysis of histograms and calculations of cell percentages in cell cycle phases were carried out using CellFit software (version 2.0). Mean proliferation indices (MPIs) were compared using the Wilcoxon matched-pair signed-rank test.
RESULTS. The MPI of pterygium fibrovascular tissue (13.4) was significantly higher than the MPI of pterygium epithelium (3.1; P = 0.0001). The MPI of pterygium fibrovascular tissue was also significantly higher than that of superior conjunctival fibrovascular tissue (6.0; P = 0.0001). There was no difference in MPI values between pterygium epithelium and superior conjunctival epithelium (3.55; P = 0.12). The MPI of fibrovascular tissue from recurrent pterygium (73.75) was significantly higher than the MPI of fibrovascular tissue from primary pterygium (7.3; P = 0.003).
CONCLUSIONS. The finding of high levels of cellular proliferation in the subepithelial fibrovascular layer of pterygium confirms that pterygium is a disorder of excessive cellular proliferation and that the fibrovascular layer is the site of cellular proliferation. Markedly raised levels of cellular proliferation in recurrent pterygium tissue suggest a clinical correlation between fibrovascular tissue upregulation and pterygium recurrence after surgery.
| Introduction |
|---|
|
|
|---|
Pterygium tissue consists of a superficial conjunctival epithelial layer and an underlying fibrovascular component. We previously determined that abnormal p53 overexpression may be present in pterygium epithelium.5 The abnormal expression of p53, a tumor suppressor gene modulating expression of growth controlling genes, which has been shown to be abnormally expressed in a wide variety of human cancers as well as actinic skin lesions,6 suggests that the epithelial layer of pterygium may be involved in the pathophysiological process of pterygium development. However, the aggressive nature of pterygium has long been noted to be related to the subepithelial fibrovascular component. Recurrent pterygium is almost always thick and fleshy, and we have recently shown that the morphology of pterygium, as determined by the degree of fibrovascular tissue present, correlates well with recurrence rates after simple bare sclera excision.7 We have also shown that the surgical technique of conjunctival rotational autografting, in which just removal of the fibrovascular component of pterygium is performed, with replacement of the original conjunctival epithelium overlying the pterygium, is a successful procedure with a low rate of recurrence of 4%.8
To further evaluate the proliferative growth process in pterygium, flow cytometry was performed in this study to compare cellular proliferation rates in the epithelium and fibrovascular layers of primary and recurrent pterygia, in comparison with matched epithelial and subepithelial layers of superior conjunctiva from these eyes.
| Methods |
|---|
|
|
|---|
Specimen Collection and Processing
Surgical excision of pterygia was carefully carried out to
separate epithelium from underlying fibrovascular tissue. In all
instances, it was possible to obtain fibrovascular pterygium tissue
without epithelium, but pterygium epithelium samples invariably
included a small amount of subepithelial tissue, because epithelium is
adherent to the fibrovascular layer via the substantia propria. In all
cases, matched specimens of superior bulbar conjunctiva, also separated
into epithelial and subepithelial layers, were collected at the time of
conjunctival autograft donor harvesting. Specimens were immediately
snap-frozen in liquid nitrogen and transferred to a -70°C freezer
before processing for flow cytometry analysis.
Single cell suspension was prepared using the method described by Thompson et al.,9 with modifications. Specimens were dissociated in RPMI 1640 medium manually in a Petri dish. Undissociated cells were removed by filtration through nylon mesh (40 µl). Cells and small particles passing through the nylon mesh were collected and centrifuged at 3000 rpm for 5 minutes. The supernatant was discarded, and the pellet was immediately used for staining. Three hundred to 500 µl of propidium iodine (PI) mix (containing 50 µg/ml PI, 0.01 M MgCl2, 0.01 M Tris, 0.2% Tritron X-100, and 1 mg/ml Rnase) was used to stain nuclear DNA in the pellet. After sufficient mix, the staining procedure was carried out in the dark for 5 minutes before flow cytometry.
Flow Cytometry Analysis
DNA content from both pterygium and superior bulbar
conjunctiva was measured by FACScan (BectonDickinson BD) equipped
with an argon laser with emission wavelength at 488 nm, and the
fluorescence of PI was collected using a 585/42 band-pass filter. The
FCM was calibrated each time with chicken erythrocyte nuclei (CEN, BD).
A maximum event of 30,000 was collected from each sample. Analysis of
the cell cycle compartments was carried out using CellFit software
(version 2.0).
Statistical Analysis
Mean proliferation index (MPI) was used to evaluate the
proliferative status, which was the ratio of (S +
G2/M) to (S + G2/M +
G0 + G1). The significance
of MPI between samples was calculated using the Wilcoxon matched-pair
signed-rank test.
| Results |
|---|
|
|
|---|
|
|
| Discussion |
|---|
|
|
|---|
The present study, in contrast, showed major differences in subepithelial fibrovascular mitotic activity between pterygium tissue and matched superior conjunctiva, with significantly higher proliferative rates in pterygium subepithelial fibrovascular tissue, and the highest proliferative rates in recurrent pterygium fibrovascular tissue. In contrast, epithelial samples did not vary significantly in mitotic status between pterygium and superior conjunctiva, suggesting that the major proliferative aspect of pterygium lies in the underlying fibrovascular layer. The cellular components of subepithelial pterygium fibrovascular tissue comprise primarily of fibroblasts and capillary blood vessel cells, both of which may be highly proliferative, and this study did not distinguish exact cellular components responsible for proliferative activity.
The use of superior bulbar conjunctiva as matched control tissue for the present study deserves some comment. It should be noted that environmental exposure of pterygium tissue, within the interpalpebral fissure, must be significantly greater than that of superior bulbar conjunctiva, and it is not surprising that prolonged sunlight or UV light exposure and other environmental conditions (such as drying) have been implicated in pterygium etiology.
Clinical evidence that the fibrovascular layer is important in pterygium growth and recurrence is seen in our randomized clinical trial comparing bare sclera excision to conjunctival autograft.7 In that study, pterygium morphology was graded according to the relative degree of fibrovascular tissue present in the body of pterygium, obscuring underlying episcleral vasculature under slit-lamp biomicroscopic examination. Atrophic pterygia, with translucent tissue at the pterygium body resulting in clear visualization of underlying episcleral vessels (and hence minimal fibrovascular tissue), were graded as T1. Thick, fleshy pterygia were graded as the least translucent (T3), denoting complete obscuration of episcleral vessels by the fibrovascular component, whereas all pterygia in which partial episcleral vessel obscuration was noted were graded as intermediate (T2). The study results showed that in bare sclera excision, pterygium recurrence was linked to the preoperative grade, with T3 pterygia having the highest recurrence rate, and T1 the lowest, providing clinical evidence that the fibrovascular component of pterygium is responsible for aggressive recurrent growth after surgery. The proliferative nature of pterygium fibrovasculature is now borne out in our present study. Additional supportive evidence that the fibrovascular component is important in recurrence comes from the fact that a low recurrence rate (4%) was encountered in our series of conjunctival rotational autograft procedures, in which only the fibrovascular component of the pterygium was removed, with the original pterygium epithelium replaced.8
The implication of our findings lies in determining new treatment measures for pterygium removal and its recurrence. Antimitotic measures have long been used in pterygium surgery to prevent recurrence, in the form of the use of mitomicin C, thiotepa, and ß-irradiation, which all act to reduce the proliferative capacity of tissues at the site of the pterygium in a nonspecific manner. Complications related to mitomicin C or ß-irradiation usually relate to an initial breakdown in surface conjunctiva, with the development of a nonhealing epithelial defect, which ultimately results in scleral necrosis and melting or secondary infective scleritis and endophthalmitis. In the light of our findings, a more focused approach to antiproliferative treatment could be targeted at underlying fibrovascular tissue while sparing overlying epithelial cells.
Finally, our finding of selective upregulation of pterygium fibroblast proliferation further supports the theory that pterygium is a proliferative growth disorder, as opposed to a simple degenerative condition, and future therapies should focus on selective reduction in proliferation in the fibrovascular layer of this lesion.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication July 27, 1999; revised December 22, 1999; accepted January 11, 2000.
Commercial relationships policy: N.
Corresponding author: Donald TiangHwee Tan, Deputy Director, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751. snecdt{at}pacific.net.sg
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Expression of p27(KIP1) and cyclin D1, and cell proliferation in human pterygium Br. J. Ophthalmol., January 1, 2008; 92(1): 157 - 157. [Full Text] [PDF] |
||||
![]() |
E. Peiretti, S. Dessi, C. Mulas, C. Abete, C. Norfo, M. Putzolu, and M. Fossarello Modulation of Cholesterol Homeostasis by Antiproliferative Drugs in Human Pterygium Fibroblasts Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3450 - 3458. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Kuo, D. Miyazaki, N. Nawata, T. Tominaga, A. Yamasaki, Y. Sasaki, and Y. Inoue Prognosis-Determinant Candidate Genes Identified by Whole Genome Scanning in Eyes with Pterygia Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3566 - 3575. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y W Wong, J Chew, H Yang, D T H Tan, and R Beuerman Expression of insulin-like growth factor binding protein-3 in pterygium tissue Br. J. Ophthalmol., June 1, 2006; 90(6): 769 - 772. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Peiretti, S. Dessi, M. Putzolu, and M. Fossarello Hyperexpression of Low-Density Lipoprotein Receptors and Hydroxy-Methylglutaryl-Coenzyme A-Reductase in Human Pinguecula and Primary Pterygium Invest. Ophthalmol. Vis. Sci., November 1, 2004; 45(11): 3982 - 3985. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Di Girolamo, R. K. Kumar, M. T. Coroneo, and D. Wakefield UVB-Mediated Induction of Interleukin-6 and -8 in Pterygia and Cultured Human Pterygium Epithelial Cells Invest. Ophthalmol. Vis. Sci., November 1, 2002; 43(11): 3430 - 3437. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |